

# Georgios Schoretsanitis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4239824/publications.pdf>

Version: 2024-02-01

122  
papers

3,180  
citations

218677

26  
h-index

189892

50  
g-index

133  
all docs

133  
docs citations

133  
times ranked

2093  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62.	3.3	787
2	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
3	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 162-174.	2.6	103
4	A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 200-214.	8.8	101
5	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	86
6	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 965-981.	3.1	69
7	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 603-621.	3.1	69
8	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , the, 2020, 7, 749-761.	7.4	66
9	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 41-48.	8.8	63
10	Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 4-10.	1.5	61
11	Clozapine Metabolism in East Asians and Caucasians. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 135-144.	1.4	58
12	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52
13	Clozapine is strongly associated with the risk of pneumonia and inflammation. <i>Annals of General Psychiatry</i> , 2020, 33, e100183.	3.1	50
14	Exploring the Prevalence of Clozapine Phenotypic Poor Metabolizers in 4 Asian Samples. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 644-648.	1.4	39
15	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1237-1253.	3.1	37
16	Around 3% of 1,300 Levels Were Elevated during Infections in a Retrospective Review of 131 Beijing Hospital In-Patients with More than 24,000 Days of Clozapine Treatment. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 255-257.	8.8	37
17	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 625-639.	3.1	34
18	Is there a future for <i>CYP1A2</i> pharmacogenetics in the optimal dosing of clozapine?. <i>Pharmacogenomics</i> , 2020, 21, 369-373.	1.3	33

#	ARTICLE	IF	CITATIONS
19	Keep at bay! “ Abnormal personal space regulation as marker of paranoia in schizophrenia. <i>European Psychiatry</i> , 2016, 31, 1-7.	0.2	32
20	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. <i>Psychoneuroendocrinology</i> , 2016, 73, 9-15.	2.7	31
21	Sertraline in pregnancy “ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Journal of Affective Disorders</i> , 2017, 212, 1-6.	4.1	31
22	The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 431-440.	3.3	31
23	Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries. <i>Revista De Psiquiatria Y Salud Mental</i> , 2022, 15, 238-250.	1.8	31
24	An update on the complex relationship between clozapine and pneumonia. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 145-149.	3.1	30
25	Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. <i>Schizophrenia Research</i> , 2019, 210, 143-148.	2.0	29
26	Using therapeutic drug monitoring to personalize clozapine dosing in Asians. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12384.	2.2	29
27	Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. <i>British Journal of Psychiatry</i> , 2022, 221, 591-602.	2.8	29
28	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 554-561.	1.4	28
29	Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 875-883.	3.1	26
30	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1091-1098.	1.9	25
31	Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2022, 24, 264-274.	1.9	24
32	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 79-102.	2.0	23
33	Pregnancy exposure to citalopram “ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 213-219.	4.8	22
34	Pharmacokinetics of risperidone in different application forms “ Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018, 28, 130-137.	0.7	22
35	Antidepressants in breast milk; comparative analysis of excretion ratios. <i>Archives of Women's Mental Health</i> , 2019, 22, 383-390.	2.6	22
36	Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: A Systematic Critical Review and Combined Analysis. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 245-254.	2.0	22

#	ARTICLE	IF	CITATIONS
37	Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. <i>Schizophrenia Research</i> , 2017, 185, 51-57.	2.0	21
38	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , 2022, 48, 296-306.	4.3	21
39	Risperidone-induced extrapyramidal side effects. <i>International Clinical Psychopharmacology</i> , 2016, 31, 259-264.	1.7	20
40	Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. <i>Clinical Pharmacokinetics</i> , 2019, 58, 535-543.	3.5	20
41	Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. <i>Clinical Pharmacokinetics</i> , 2021, 60, 329-335.	3.5	20
42	Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. <i>Journal of Psychopharmacology</i> , 2016, 30, 803-809.	4.0	19
43	Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2019, 33, 1201-1222.	5.9	19
44	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 140-147.	1.4	19
45	Reduced clearance of venlafaxine in a combined treatment with quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 116-121.	4.8	18
46	Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110228.	4.8	18
47	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. <i>Journal of Affective Disorders</i> , 2018, 227, 506-511.	4.1	16
48	Dose and safety concerns of clozapine: Worldwide package inserts need revisions. <i>Schizophrenia Research</i> , 2020, 216, 2-4.	2.0	16
49	Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 308-310.	1.4	16
50	The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 353-371.	1.6	16
51	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	16
52	Pregnancy exposure to quetiapine – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. <i>Schizophrenia Research</i> , 2018, 195, 252-257.	2.0	15
53	Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	2.2	15
54	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2018, 57, 729-737.	3.5	14

#	ARTICLE	IF	CITATIONS
55	Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review. <i>Journal of Psychopharmacology</i> , 2021, 35, 1062-1073.	4.0	14
56	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. <i>European Neuropsychopharmacology</i> , 2022, 60, 25-37.	0.7	14
57	Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 325-333.	3.2	13
58	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. <i>Journal of Psychopharmacology</i> , 2021, 35, 273-278.	4.0	13
59	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	1.7	12
60	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. <i>European Neuropsychopharmacology</i> , 2020, 35, 1-11.	0.7	12
61	Clozapine and the risk of haematological malignancies. <i>Lancet Psychiatry</i> , 2022, 9, 537-538.	7.4	12
62	Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1668-1675.	2.4	11
63	Upon Rejection: Psychiatric Emergencies of Failed Asylum Seekers. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1498.	2.6	11
64	Polycystic ovary syndrome and postpartum depression: A systematic review and meta-analysis of observational studies. <i>Journal of Affective Disorders</i> , 2022, 299, 463-469.	4.1	11
65	An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine. <i>Annals of General Psychiatry</i> , 2022, 35, e100773.	3.1	11
66	Gemfibrozil May Decrease Norclozapine Elimination. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 405-407.	1.4	10
67	Pregnancy exposure to venlafaxine—Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. <i>Journal of Affective Disorders</i> , 2020, 266, 578-584.	4.1	10
68	Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland. <i>Journal of Personalized Medicine</i> , 2022, 12, 441.	2.5	10
69	How to Treat Hypertension in Venlafaxine-Medicated Patients—Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 498-501.	1.4	9
70	Inferior frontal gyrus gray matter volume is associated with aggressive behavior in schizophrenia spectrum disorders. <i>Psychiatry Research - Neuroimaging</i> , 2019, 290, 14-21.	1.8	9
71	Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 687.	2.8	9
72	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 986-996.	4.3	9

#	ARTICLE	IF	CITATIONS
73	Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 531-541.	2.5	9
74	No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 110-122.	4.5	8
75	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1109-1116.	1.9	8
76	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. <i>International Clinical Psychopharmacology</i> , 2019, 34, 241-246.	1.7	8
77	Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 303-308.	2.5	8
78	Interaction Between Risperidone, Venlafaxine, and Metronidazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 730-733.	1.4	7
79	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 101-106.	4.8	7
80	Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, <i>CYP2D6</i> and <i>ABCB1</i> variants. <i>Pharmacogenomics</i> , 2018, 19, 815-823.	1.3	7
81	Psychiatric Emergencies of Asylum Seekers; Descriptive Analysis and Comparison with Immigrants of Warranted Residence. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1300.	2.6	7
82	High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers. <i>Revista Colombiana De Psiquiatria</i> , 2020, 49, 84-95.	0.3	6
83	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 537-540.	3.2	6
84	Anatomy Lessons by the Amsterdam Guild of Surgeons. <i>Medical Education and Art. Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2018, 90, 267-273.	0.1	5
85	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 851-857.	3.2	5
86	Studies of Half-Lives of Long-Acting Antipsychotics are Needed. <i>Pharmacopsychiatry</i> , 2019, 52, 45-46.	3.3	5
87	<i>CYP2D6</i> pharmacogenetics and risperidone: reflections after 25 years of research. <i>Pharmacogenomics</i> , 2020, 21, 1139-1144.	1.3	5
88	Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1111-1119.	2.4	5
89	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. <i>Pharmacopsychiatry</i> , 2021, 54, 31-35.	3.3	5
90	Core clinical manifestations of clozapine-related DRESS syndrome: A network analysis. <i>Schizophrenia Research</i> , 2022, 243, 451-453.	2.0	5

#	ARTICLE	IF	CITATIONS
91	Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1059-1060.	2.3	4
92	Prenatal complications and neurodevelopmental outcomes in offspring: interactions and confounders. Acta Psychiatrica Scandinavica, 2020, 142, 261-263.	4.5	4
93	Changes in Clozapine Bioavailability in a Percutaneous Endoscopic Gastrostomy-Fed Patient With Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2020, 40, 306-308.	1.4	4
94	The role of cytochrome P450 enzyme genetic variants in cannabis hyperemesis syndrome—A case report. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 82-85.	2.5	4
95	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1437-1443.	3.2	4
96	Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2141-2150.	2.2	4
97	Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 41-48.	2.0	4
98	Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome. Expert Opinion on Drug Safety, 2022, 21, 585-587.	2.4	4
99	The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine—A case report. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 354-357.	2.5	3
100	Acute Psychiatric Problems among Migrants Living in Switzerland- a Retrospective Study from a Swiss University Emergency Department. Emergency Medicine: Open Access, 2016, 6, .	0.1	3
101	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. Pharmacopsychiatry, 2020, 53, 65-70.	3.3	2
102	Prolactin changes during electroconvulsive therapy: A systematic review and meta-analysis. Journal of Psychiatric Research, 2020, 128, 25-32.	3.1	2
103	Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. Revista De Psiquiatria Y Salud Mental, 2022, 15, 117-133.	1.8	2
104	Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. Expert Review of Clinical Pharmacology, 2022, 15, 243-249.	3.1	2
105	Promoting safer clozapine dosing in the Americas. Revista Brasileira De Psiquiatria, 2022, , .	1.7	2
106	Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia Research, 2020, 218, 309-311.	2.0	1
107	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. Clinical Pharmacokinetics, 2021, 60, 1583-1589.	3.5	1
108	Reply to the Comments by Doherty et al.. Psychotherapy and Psychosomatics, 2021, 90, 140-141.	8.8	1

#	ARTICLE	IF	CITATIONS
109	Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene. <i>Schizophrenia Research</i> , 2020, 224, 178-179.	2.0	0
110	Authors'™ Reply to Suhas et al.: Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation". <i>Clinical Pharmacokinetics</i> , 2021, 60, 1077-1079.	3.5	0
111	Antenatal Antidepressant Prescription Associated With Reduced Fetal Femur Length but Not Estimated Fetal Weight. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 571-578.	1.4	0
112	The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine. <i>Pharmacopsychiatry</i> , 2018, 51, .	3.3	0
113	The clinical relevance of the pharmacological interaction between clozapine and sertraline. , 2019, 52, .		0
114	Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. , 2020, , 1-24.		0
115	Patterns of clozapine pharmacokinetics in patient subgroups with different body mass index. , 2020, 53, .		0
116	22 Using TDM"to improve efficacy and safety outcomes of antipsychotic treatment. <i>Pharmacopsychiatry</i> , 2020, 53, .	3.3	0
117	Esketamine for treatment-resistant depression in adults. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
118	Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis. <i>Pharmacopsychiatry</i> , 2022, , .	3.3	0
119	Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. <i>Revista De Psiquiatra Y Salud Mental (English Edition)</i> , 2022, 15, 117-133.	0.3	0
120	Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. <i>Pharmacopsychiatry</i> , 2022, , .	3.3	0
121	The therapeutic reference range for olanzapine revised " how to combine old and new findings. <i>Pharmacopsychiatry</i> , 2022, , .	3.3	0
122	Is it Time to Reevaluate the Therapeutic Reference Range for the Antidepressant Drug Venlafaxine?. <i>Pharmacopsychiatry</i> , 2022, , .	3.3	0